De Wit R New Hope for Patients with Metastatic Hormone-Refrectory Prostate Cancer Eur Urol. 2006, 5:

Transcription

1 Tannock IF,, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Eng J Med 2004; 351: Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE,, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, De Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia Del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, Von Der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C European Consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone finally an effective chemotherapy. Eur J Cancer 2005; 41: Blower P,, Goodin S, Aapro M Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005; 55: Oliver RTD, Mason MD, Mead GM, Von der Maase H, Rustin GJS, Joffe JK,, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP for the MRC TE19 collaborators and the EORTC collaborators Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005; 366: Fossa SD, Paluchowska B, Horwich A, Kaiser G, De Mulder PHM, Korakine O, Van Oosterom AT, De Prijck L, Collette L, and the EORTC GU Group Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 2005; 93: Van de Belt-Dusebout AW, Nuver J,, Gietema JA, Ten Bokkel Huinink WW, Rodrigus PTR, Schimmel EC, Aleman BMP, Van Leeuwen FE Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006 ; 24: Loos WJ, De Jongh FE, Sparreboom A,, Van Boven-Van Zomeren DM, Stoter G, Nooter K, Verweij J Evaluation of an Alternate Dosing Strategy for Cisplatin in Patients With Extreme Body Surface Area Values. J Clin Oncol 2006; 24: New Hope for Patients with Metastatic Hormone-Refrectory Prostate Cancer Eur Urol. 2006, 5: , Fizazi K Controversies in the management of clinical stage I testis cancer; are all options equal? J Clin Oncol 2006, 24: Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fossa SD, Gerl A,, Roberts JT,

2 Habbema JD Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 Patients. Eur Urol. 2007; 51: Loos WJ,, Freedman SJ, Van Dijck K, Gambale JJ, Li S, Murphy GM, Van Noort C, De Bruijn P, Verweij J Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 2007; 57: Armstrong AJ, Garrett-Mayer ES, Yang YCO, Carducci MA, Tannock IF,, Eisenberger MA Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: Van den Belt-Dusebout AW,, Gietema JA, Horenblas S, Louwman M, Ribot J, Hoekstra HJ, Ouwens G, Aleman BMP, Van Leeuwen FE Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer (CTA). J Clin Oncol 2007; 25: Loos WJ, Zamboni WC, Engels FK, De Bruijn P, Lam MH,, Verweij J, Wiemer EA Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. J Pharm Biomed Anal 2007; 45: Armstrong AJ, Garrett-Mayer ES, Ou Yang YC,, Tannock IF, Eisenberger M A contemporary prognostic nomogram for men with Hormone-Refractory metastatic Prostate Cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: Cutting back on computed tomography scan frequency in curative oncology: get the picture. J Clin Oncol 2007; 25: Refining the optimal chemotherapy regimen in good prognosis germ cell cancer: interpretation of the current body of knowledge. J Clin Oncol 2007; 25: Optimal management of retroperitoneal metastatic management of non-seminomatous testicular cancer; towards better selection between scalpel and needle. J Clin Oncol 2007; 35: , Sleijfer S, Kaye SB, Horwich A, Mead B, Sleijfer DT, Stoter G Bleomycin and scuba diving: where is the harm? Lancet Oncol 2007; 8: Van Casteren N, Stoop H, Dohle G,, Oosterhuis J, Looijenga L Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4 Eur Urol 2008; 54: Berthold DR, Pond GR, Soban F,, Eisenberger MA, Tannock IF Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 2008; 26: Sissung TM, Danesi R, Price DK, Steinberg SM,, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

3 Mol Cancer Ther 2008; 7:19-26 Berthold DR, Gregroy RP, Roessner M,, Eisenberger M, Tannock IF Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between PSA, pain and quality of life response and survival in the Tax-327 study Clin Cancer Res 2008; 14: Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, De Wit M,, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, Von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I Eur Urol 2008; 53: Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, De Wit M,, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, Von der Maase H. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II Eur Urol 2008; 53: Hamberg P, Verhagen PCMS,. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008; 44: Berthold DR, Pond GR,, Eisenberger M, Tannock IF: on behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 2008; 19: Chemotherapy in hormone-refractory prostate cancer Br J Urol Int 2008; 101 Suppl 2: 11-15, Van den Bent M, Kirkels W. The management of cerebral metastasis from germ cell cancer; walking the tightrope Eur J Cancer 2008 Aug;44(12): Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N,, et al. Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach Crit Rev Onc Hematol Oct;68 Suppl 1:S9-S22 Armstrong AJ, Halabi S,, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with

4 castration-resistant metastatic prostate cancer Prostate Cancer Prostatic Dis. 2009;12(1): doi: /pcan Epub 2008 Jun 24. Van Weerden WM, Bangma C,. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer Br J Cancer Jan 13;100(1):13-8. doi: /sj.bjc Epub 2008 Dec 16. Fitzpatrick JM, Sternberg CN, Saad F, Extermann M, Caffo O, Halabi S, Kramer G, Oudard S, Treatment decisions for advanced genitourinary cancers: from symptoms to risk assessment Eur Urol Suppl. 2009;8(9): Meulenbeld HJ, Hamberg P, Chemotherapy in patients with castration-resistant prostate cancer Eur J Cancer Sep;45 Suppl 1: doi: /S (09) De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S,, Sylvester R Randomized phase II/III trail assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients with advanced urothelial cancer unfit for cisplatin-based chemotherapy: phase II-results of EORTC study 30986, J Clin Oncol Nov 20;27(33): doi: /JCO Epub 2009 Sep 28. Troost MM, Sternberg CN, Management of good risk germ-cell tumours BJU Int Nov;104(9 Pt B): doi: /j X x. Van den Belt-Dusebout AW, Aleman BMP, Besseling G, De Bruin ML, Hauptmann M, Van t Veer MB,, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy Int J Radiat Oncol Biol Phys Dec 1;75(5): doi: /j.ijrobp Armstrong AJ, Tannock IF,, George DJ, Eisenberger M, Halabi S The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer Feb;46(3): doi: /j.ejca Epub 2009 Dec 11. Armstrong AJ, Garrett-Mayer E,, Tannock I, Eisenberger M Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res Jan 1;16(1): doi: / CCR Epub 2009 Dec 15. Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S Circulating Endothelial Cells, Circulating Tumour Cells, Tissue Factor, Endothelin-1 and Overall Survival In Prostate Cancer Patients Treated With Docetaxel Eur J Cancer Jul;46(11): doi: /j.ejca Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Albers P, Albrecht W, Algaba F, Bamias A, Bodrogi I, Cohn-Cedermark G, Culine S, Cullen M, Daugaard G, De Santis M,, Derigs G, Dieckmann K, Droz JP, Einhorn L, Fléchon A, Fossa S, Solans JG, Gauler T, Géczi L, Lluch JR, Gillessen S, Gosporadowicz M, Hartmann M, Huddart R, Jewett M, Joffe J, Jordan K, Kataja V, Klepp O, Kollmannsberger C, Krege S, Looijenga L, Mead GM, Necchi A, Nichols C, Nicolai N, Oliver T, Ondrus D, Osterhuis W, Paz-Ares L, Powles T, Pottek T, Rajpert-De Meyts E, Rosti G, Rustin G, Salvioni R, Schmidberger H, Sedlmayer F, Sella A, Sippel C, Skakkebaek NE, Souchon R, Sohaib A, Tjulandin S, Van den Belt-Dusebout AW, Von der Maase H, Warde P, Wood L Testicular seminoma: ESMO Clinical Practive Guidelines for diagnosis, treatment and follow-up Ann Oncol May;21 Suppl 5:v doi: /annonc/mdq176.

5 Schmoll HJ, Laguna MP, Fizazi K, Horwich A, Albers P, Albrecht W, Algaba F, Bamias A, Bodroi I, Cohn-Cedermark G, Culine S, Cullen M, Daugaard G, De Santis M,, Derigs G, Dieckman K, Droz JP, Einhorn L, Fléchon A, Fossa S, Foster RS, Solans JG, Gauler T, Géczi L, Lluch JR, Gillessen S, Gosporadowicz M, Hartmann M, Huddart R, Jewett M, Joffe J, Jordan K, Kataja V, Klepp O, Kollmannsberger C, Krege S, Looijenga L, Mead GM, Necchi A, Nichols C, Nicolai N, Oliver T, Ondrus D, Osterhuis W, Paz-Ares L, Powles T, Pottek T, Rajpert-De Meyts E, Rosti G, Rustin G, Salvioni R, Schmidberger H, Sedlmayer F, Sella A, Sippel C, Skakkebaek NE, Sohaib A, Tjulandin S, Van den Belt-Dusebout AW, Von der Maase H, Warde P, Wood L Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up Ann Oncol May;21 Suppl 5:v doi: /annonc/mdq177. Sonpavde G, Pond GR, Bery WR,, Armstrong AJB, Eisenberger MA, Tannock IF Serum alkaline phosphate changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy Urol Oncol Sep;30(5): doi: /j.urolonc Epub 2010 Oct 2. Daugaard G, Skoneczna I, Aass N,, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ A randomized phase III study comparing standard dose BEP with sequential high-dose Cisplatin, Etoposide, Ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer. An intergroup study of EORTC, GTCSG and Grupo Germinal (EORTC 30974) Ann Oncol May;22(5): doi: /annonc/mdq575. Epub 2010 Nov 8. Van den Belt-Dusebout AW, Aleman B, Gietema JA,, Van t Veer MB, Lugtenburg PJ, Krol AD, Van Leeuwen FE Long-term complications following treatment of testicular cancer and Hodgkin lymphoma Ned Tijdschr Geneeskd. 2010;154(45):A2229. Sonpavde G, Pond GR, Berry WR,, Eisenberger MA, Tannock IF, Armstrong AJ The association between radiographic respons and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy Cancer Sep 1;117(17): doi: /cncr Epub 2011 Mar 1. Scher HI, Jia X, Chi K,, Berry W, Albers P, Henick B, Waterhouse D, Ruether DJ, Watkins DL, Rosen PJ, Meluch A, Nordquist L, Nietzsch D, Gleibner J, Tkacova V, Venner P, Heidenreich A, Chu L, Heller G A Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol versus Docetaxel Plus Prednisone for Patients with Castration-Resistant Prostate Cancer J Clin Oncol Jun 1;29(16): doi: /JCO Epub 2011 Apr 11. Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR,, Eisenberger Tannock IF, Sonpavde G Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer Eur Urol Feb;61(2): doi: /j.eururo Epub 2011 Jun 22. MA, De Vos FYFL, Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy Ther Adv Med Oncol Nov;2(6): doi: / Albrecht W, Becker J, Belderbos JS, Bernier J, Cogneti F, Coleman RE, Conroy T,, Eggermont A, Fossa A, Giaccone G, Horiot JC, Keilholz U, Keuppens F, Koehne CH, Lefebvre JL, Levi F, Oosterhof GO, Piccart M, Postmus P, Schmoll HJ, Schutser-Uitterhoeve AL, Smit EF, Splinter TA, Taphoorn M, Therasse P, Van den Bent MJ, Van Meerbeek J, Van Poppel H, Van Zandwijk N Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data Expert Rev Pharmacoecon Outcomes Res Oct;11(5): doi: /erp De Santis M, Bellmunt J, Mead G, Kerst M, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G,

6 Skoneczna I, Collette S, Lorent J,, Sylvester R Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study J Clin Oncol Jan 10;30(2): doi: /JCO Epub 2011 Dec 12. Meulenbeld HJ, Mathijssen RH, Verweij J,, De Jonge MJ Danusertib, and aurora kinase inhibitor Expert Opin Investig Drugs Mar;21(3): doi: / Epub 2012 Jan 13., Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L Randomized Phase III Study Comparing Paclitaxel-Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell cancer: Intergroup Study EORTC J Clin Oncol Mar 10;30(8): doi: /JCO Epub 2012 Jan 23. Bellmunt J, Von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A,Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester S, Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study J Clin Oncol Apr 1;30(10): doi: /JCO Epub 2012 Feb 27. Schaapveld M, Van den Belt-Dusebout AW, Gietema JA,, Horenblas S, Witjes AJ, Hoekstra HJ, Kiemeney LALM, Louwman MWJ, Ouwens GM, Aleman BMP, Van Leeuwen FE Risk and prognostic significance of metachronous contralateral testicular germ cell tumors Br J Cancer Oct 23;107(9): doi: /bjc Epub 2012 Oct 11. Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fossa SD, Polee M, Gerritsen W, Dalesio O, de Wit R Randomised phase II/III study of docetaxel woth or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer Nov;48(16): doi: /j.ejca Epub 2012 Jun 6., Daugaard G, Albers P, White JD, Germa Lluch JR. Design of Testis Cancer Trials: Who Knows Best? J Clin Oncol Sep 1;30(25):3145-6; author reply doi: /JCO Epub 2012 Jul 23. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, the AFFIRM Investigators Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy N Engl J Med Sep 27;367(13): Epub 2012 Aug 15. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int Jan;111(1): doi: /j X x. Epub 2012 Aug 29. Schaapveld M, Van den Belt-Dusebout AW, Gietema JA,, Horenblas S, Witjes AJ, Hoekstra HJ, Kiemeney LALM, Louwman MWJ, Ouwens GM, Aleman BMP, Van Leeuwen FE Risk and prognostic significance of metachronous contralateral testicular germ cell tumors Br J Cancer Oct 23;107(9): doi: /bjc Epub 2012 Oct 11. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit

7 R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LHJ, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C Maintaining Success, Reducing Treatment Burden, Focusing on Survivorship: Highlights from the Third European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer. Ann Oncol Apr;24(4): doi: /annonc/mds579. Epub 2012 Nov 14. Niraula S, Pond G, de Wit R, Eisenberger M, Tannock IF, Joshua AM. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J Jan-Feb;7(1-2):E Doi: /cuaj.267 Verhoeven RH, Karim-Kos HE, Coebergh JW, Brink M, Horenblas S,, Kiemeney BA Markedly increased incidence and improved survival of testicular cancer in the Netherlands Acta Oncol Mar;53(3): doi: / X Epub 2013 Aug 30. Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA. Adjuvant Leuprolide With or Without Docetaxel in High-Risk Prostate Cancer After Radical Prostatectomy (TAX-3501): Important Lessons for Future Trials Cancer Oct 15;119(20): doi: /cncr Epub 2013 Aug 13. Meulenbeld HJ, De Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR,. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRCP). Cancer Chemother Pharmacol Oct;72(4): doi: /s Epub 2013 Aug 7. Pond GR, Sonpavde G,, Eisenberger MA, Tannock IF, Armstrong AJ. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol Jan;65(1):3-6. doi: /j.eururo Epub 2013 Oct 5. Fitzpatrick JM,. Taxane mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer. Eur Urol Jun;65(6): doi: /j.eururo Epub 2013 Jul 25. van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castrationresistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. Eur Urol Aug 11. doi:pii: S (13) /j.eururo [Epub ahead of print] Gerritse FL, Meulenbeld HJ, Roodhart JM, van der Velden AM, Blaisse RJ, Smilde TJ, Erjavec Z, de Wit R, Los M; NePro Study Investigators. Analysis of docetaxel therapy in elderly ( 70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer Oct;49(15): doi: /j.ejca Epub 2013 Jul 9. de Wit R, Bosl GJ. Optimal management of clinical stage I testis cancer: one size does not fit all. J Clin Oncol Oct 1;31(28): doi: /JCO Epub 2013 Sep 3. van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

8 Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer Dec;49(18): doi: /j.ejca Epub 2013 Oct 24. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E,, Eisenberger MA, Tannock IF. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate (mcrpc) in the TAX 327 trial. J Geriatr Oncol Apr;5(2): doi: /j.jgo Epub 2014 Jan 2. cancer Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou A, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson C, De Santis M, Seruga B, de Wit R. Optimal Management of Metastatic Castration-Resistant Prostate Cancer: Hightlights from a European Expert Consensus Panel. Eur J Cancer Jun;50(9): doi: /j.ejca Epub 2014 Apr 3. van Leeuwen M, Efficace F, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll Franse LV, van Poppel H, White J, Collette L, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group; Radiation Oncology Group. Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities. Eur J Cancer Jul;50(11): doi: /j.ejca Epub 2014 May 9. van Soest RJ, de Wit R, van Weerden WM. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Eur Urol. In press. Eur Urol Jul 7. pii: S (14) doi: /j.eururo [Epub ahead of print] No abstract available.